Align your Market Access and Pricing Strategy with Insights from key decision-makers from pCPA, PMPRB, CADTH and INESSS. Gain a critical analysis of Canada’s access and reimbursement environment, and in-depth discussions on how to adapt market access strategies — especially at a time when affordability and overall health system sustainability are top of mind.

Special Keynote Speaker
Speaker Name

Susan Fitzpatrick

Head
Canadian Drug Agency Transition Office

CONFERENCE CO-CHAIRS
Speaker Name

Farah Jivraj

Head, Market Access and Stakeholder Relations
Biogen

Speaker Name

Dipti Tankala

Manager, Market Access & HEOR
AbbVie

FEATURED SPEAKERS
Speaker Name

Sylvie Bouchard

Director, Drug Evaluation and Technology Assessment for Reimbursement
INESSS

Speaker Name

Paul Kryzanowski

Medical Director, Precision Medicine
The Janssen Pharmaceutical Companies of Johnson & Johnson

Speaker Name

Tanya Potashnik

Director, Policy and Economic Analysis
Patented Medicine Prices Review Board

Speaker Name

Fred Little

Country Lead Rare Disease
Pfizer

Speaker Name

Kiersten Combs

Country President, Canada
AstraZeneca

PROGRAM HIGHLIGHTS:
  • BUILD a market access and pricing plan for 2023 with insights from key regulators and industry leaders
  • CONNECT directly with drug review, and decision-makers from CADTH, PMPRB, pCPA, and INESSS
  • DISCOVER the true potential of the use of RWE for HTA and reimbursement decisions in Canada
  • ANTICIPATE the impact of the national pharmacare strategy on patients and payers
  • PREPARE drugs submissions that align private payer priorities
  • EXAMINE how to improve health outcomes through improved access to advanced diagnostic testing
WHO YOU WILL MEET

Practitioners at every level with experience in:

  • Pricing
  • Reimbursement
  • Market access
  • Patient access
  • Government and regulatory affairs
  • Health economics
  • Research and development
  • Policy and compliance
  • Pharmacy services
  • Marketing
  • National trade
  • Formularies
  • Business development
  • Sales

From brand generic and manufacturing companies involved in:

  • Product development
  • Public drug programs
  • Pharmaceutical benefits
  • Pharmaceutical strategy
  • Drug submissions
  • Formulary management
  • Policy and economic analysis
  • Provider services and
  • relations
  • Pharmacy

And representatives from:

  • Associations
  • Patient Advocacy Groups
About this Conference

The pandemic has put a spotlight on gaps in Canada’s healthcare system, and further demonstrated how crucial it is to have timely access to innovative medicines. As the world emerges from a period characterized by rapid adaptation, and response, stakeholders will need to translate key lessons learned into collaborative action aimed at creating new market access pathways and drug funding models.

This annual forum will host critical conversations, examining the most vexing questions and challenges hovering over manufacturers, payers, and patient groups alike, while also exploring opportunities to empower decision-making so that the right treatment reaches patients at the right time.

Join us at this highly anticipated market access event to share best practices, participate in candid discussions, and hear the latest developments from leading drug manufacturers and other industry leaders.

RECORDED EVENTS

Webinar Recording

PMPRB Modernization and New Regulations: How to Navigate the Transition into a New Regulatory Regime for Drug Pricing in Canada

FREE DOWNLOAD
Testimonials
Quote Icon

Great overview, gave me a different perspective. Got me thinking differently.

Team Lead, Pricing and Contracts, GSK
Quote Icon

I liked the quality of the speakers.

Manager, Market Access and HTA, BMS
Quote Icon

Overall excellent topics and speakers. Truly enjoyed the selection of speakers and the panels.

Manager, Pricing and Contracts, Astellas:
Related Conferences
Event Thumbnail Image
Event Thumbnail Image
Event Thumbnail Image